Alar Pharmaceuticals (6785) has a market capitalization of approximately NT$7.4B, trading at NT
Alar Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Alar Pharmaceuticals runs a net profit margin of -3755.2%, a gross margin of -72.1%, and an operating margin of -6290.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Alar Pharmaceuticals reported revenue of NT
Alar Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Alar Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 25.01x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alar Pharmaceuticals (6785) the key facts are: market cap NT$7.4B, revenue NT
Get Alar Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.